Scimago Lab
powered by Scopus
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 2329-0358

Get your full text copy in PDF

The Incidence of Malignancy in Heart Transplant Recipients

M Garlicki, K Wierzbicki, P Przybylowski, D Drop, M Biernat, P Rudzinski, B Olszewska, A Dziatkowiak

Ann Transplant 1998; 3(4): 41-47

ID: 497430

Objectives and methods: 219 heart transplant recipients with survival over 3 months were retro- and prospectively analysed for the incidence of primary neoplasms. Patients received immunosuppressive drugs (cyclosporine A, azathioprine,steroids) with a 4-5 days induction course of Rabbit Anti-Thymocyte Immunoglobulin (RATG) or monoclonal antibodies induction /OKT3/ in some cases. Anti-rejection treatment consisted of pulse doses of methyloprednisolon or RATG. Results: 9 cases of malignancy (4,1%) with one case of pre-malignant liver condition (dysplasia gigantocellulare, 0.45%) were found (8M; IF; age: 45-67 y.o., x 57.7). Symptoms of neoplasms occurred 7-79 months (x 31,4) postoperatively. Skin carcinomas: planoepitheliale, spinocellulare, soft tissue neoplasms / mesenchymal sarcoma, larynx Ca planoepitheliale, lung: adenocarcinoma and Ca microcellulare, kidney Ca clarocellulare and post transplant non-Hodgkin lymphoma were diagnosed. Chemo- and radiotherapy, surgery and reduction of immunosuppression did not change the outcome of malignancy in 6 pts.; (regression- I pt was., remission- 2 pts). Patients died 7-86 months after Htx (x 41), 4-25 mos. (x 12.5) after suffering from first symptoms and 0-10 months (x 4,9) after pathology-based diagnosis of neoplasm. Conclusions:Heart transplant recipientshave an increased riskof carcinogenesis.The incidence of malignancies in the studied group is similar or even lower than in other reports.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree